In a non-alcoholic fatty liver disease (NAFLD) model, CGA increased the expression of tight junction proteins occludin and ZO-1 in intestinal tissue, decreased the LPS levels, and increased the level of glucagon-like peptide 1 (GLP-1) in the portal vein [85]. This evidence concerns the gene OCLN and metabolic dysfunction-associated steatotic liver disease.